Off-the-shelf vaccine shows promise in preventing cancers returning, study finds
A non-mRNA vaccine has shown potential in preventing the recurrence of pancreatic and colorectal cancers, according to recent research. The vaccine targets common mutations found in these cancer types and could lower the risk of relapse. The study is part of the NHS in England's Cancer Vaccine Launch Pad (CVLP) program, which is exploring various cancer vaccine trials. Unlike the mRNA vaccines developed for COVID-19, this off-the-shelf vaccine does not use the same technology. The findings suggest this alternative approach may offer a promising avenue for cancer prevention, particularly for patients who have already undergone treatment for pancreatic or colorectal cancer and are at risk of the disease returning. The research highlights the ongoing efforts to develop effective cancer vaccines that could improve outcomes for patients.
Note: This is an AI-generated summary of the original article. For the full story, please visit the source link below.
